Stockscreener 앱 받기
0.20%
시간 외 거래:
전일 마감가:
$709.80
열려 있는:
$707.2
하루 거래량:
395.70K
Relative Volume:
0.48
시가총액:
$88.83B
수익:
$359.05B
순이익/손실:
$3.30B
주가수익비율:
27.53
EPS:
25.83
순현금흐름:
$5.23B
1주 성능:
-0.61%
1개월 성능:
-1.35%
6개월 성능:
+21.35%
1년 성능:
+22.59%
1일 변동 폭
$702.00
$714.53
1주일 범위
$700.50
$718.00
52주 변동 폭
$464.42
$737.89
맥케슨 Stock (MCK) Company Profile
명칭
Mckesson Corporation
전화
972-446-4800
주소
6555 STATE HIGHWAY 161, IRVING, TX
MCK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MCK
Mckesson Corporation
|
711.21 | 89.38B | 359.05B | 3.30B | 5.23B | 25.83 |
|
COR
Cencora Inc
|
292.67 | 57.58B | 310.23B | 1.69B | 3.58B | 8.62 |
|
CAH
Cardinal Health Inc
|
158.58 | 38.59B | 222.29B | 1.56B | 2.44B | 6.41 |
|
HSIC
Henry Schein Inc
|
69.07 | 8.84B | 12.50B | 314.00M | 421.00M | 2.44 |
|
AHG
Akso Health Group Adr
|
2.025 | 658.06M | 2.22M | -5.63M | -1.68M | -0.24 |
맥케슨 Stock (MCK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-04 | 재개 | Mizuho | Neutral |
| 2024-11-07 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-09-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-09-05 | 재확인 | Leerink Partners | Outperform |
| 2024-08-08 | 재확인 | Mizuho | Neutral |
| 2024-02-26 | 개시 | Leerink Partners | Outperform |
| 2024-01-03 | 개시 | Barclays | Overweight |
| 2023-12-14 | 개시 | Wells Fargo | Equal Weight |
| 2023-03-31 | 개시 | Citigroup | Buy |
| 2022-08-22 | 재개 | Morgan Stanley | Overweight |
| 2022-07-06 | 다운그레이드 | Argus | Buy → Hold |
| 2022-06-07 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-04-01 | 재개 | Credit Suisse | Outperform |
| 2022-02-04 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-01-07 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2021-11-02 | 재확인 | Barclays | Overweight |
| 2021-11-02 | 재확인 | BofA Securities | Buy |
| 2021-11-02 | 재확인 | Evercore ISI | Outperform |
| 2021-11-02 | 재확인 | Jefferies | Buy |
| 2021-03-30 | 업그레이드 | Argus | Hold → Buy |
| 2020-11-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-08-04 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2020-05-22 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-05-15 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-23 | 재개 | Credit Suisse | Neutral |
| 2020-03-18 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-02-07 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-12 | 개시 | Deutsche Bank | Hold |
| 2019-08-05 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2019-07-22 | 개시 | Guggenheim | Neutral |
| 2019-01-17 | 개시 | UBS | Neutral |
| 2018-10-26 | 재확인 | Barclays | Equal Weight |
| 2018-07-20 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2018-05-29 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-03-08 | 개시 | Barclays | Equal Weight |
| 2018-02-27 | 재개 | BofA/Merrill | Buy |
| 2018-02-02 | 재확인 | Mizuho | Neutral |
| 2018-01-24 | 업그레이드 | Jefferies | Hold → Buy |
모두보기
맥케슨 주식(MCK)의 최신 뉴스
McKesson Amplify Reaches All 50 States - McKesson
What analysts say about McKesson Corporation stockUnmatched market performance - Autocar Professional
Pharmacy Automation Market Surges with 10.12% CAGR; AI & Retail Pharmacy Demand Transform Dispensing in 2025 - GlobeNewswire Inc.
McKesson Corporation Stock Analysis and ForecastExtraordinary earning power - jammulinksnews.com
Rated R Meaning Nausea Relief Reliefband® Sport Wrist BandMcKesson Rated R Superstar Cope Logo - roarmag.org
Is McKesson (MCK) an Overlooked Dividend Stock in the Pharma Sector for 2025? - MSN
Is McKesson Corporation a good long term investmentFree Capital Growth Strategies - Jammu Links News
14 Best Pharma Dividend Stocks to Buy in 2025 - Insider Monkey
Q&A: Pharmacist's Voices Help Propel Industry Changes | McKesson ideaShare - Drug Topics
What to Expect From McKesson's Q1 2026 Earnings Report - MSN
Published on: 2025-07-18 12:27:46 - jammulinksnews.com
Lobbying Update: $460,000 of MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS lobbying was just disclosed - Quiver Quantitative
McKesson Disputes Rite Aid Trust's Antitrust Claim Demands - Law360
McKesson Corporation's Q1 2026 Earnings Preview and Stock PerformanceNews and Statistics - IndexBox
McKesson Keeps Delivering As Specialty Drugs Drive Growth - Finimize
What To Expect From McKesson's Q1 2026 Earnings Report - Barchart.com
McKesson (MCK): Morgan Stanley Raises Price Target to $810 | MCK Stock News - GuruFocus
McKesson (MCK) Sees Price Target Boost from Morgan Stanley | MCK Stock News - GuruFocus
McKesson ideaShare Empowers Independent Pharmacies to Innovate and Thrive - Yahoo Finance
Mckesson CEO Tyler S. Brian sells $13.7m in stock By Investing.com - Investing.com South Africa
Mckesson CEO Tyler S. Brian sells $13.7m in stock - Investing.com
Synergy (NASDAQ: SNYR) Strategic Partnership w/ McKesson - openPR.com
Conference Recap: McKesson ideaShare Showcases Power of Independent Pharmacies - Drug Topics
McKesson (MCK) Partners with Synergy CHC for Canadian Distributi - GuruFocus
Synergy CHC Corp. (NASDAQ: SNYR) Secures Retail Deals with McKesson Canada and Others as FOCUSfactor Expansion Surges Across North America - The Manila Times
Government Contract Update: $1B payment to MCKESSON CORPORATION - Quiver Quantitative
McKesson ideaShare 2025: Pharmacy of the Year Finalist Keri Bates Reflects on Teamwork, Community, and the Road Ahead - Pharmacy Times
Independent Pharmacies Face Mounting Challenges in Modern Health Care Landscape | McKesson ideaShare - Drug Topics
McKesson Corporation (MCK): If It Was Down, I’d Say “Fill Her Up,” Says Jim Cramer - MSN
McKesson's Commitment to Independent Community Pharmacies Takes Center Stage | McKesson ideaShare - Drug Topics
McKesson ideaShare 2025: Pharmacy Technicians Drive Efficiency and Care - Pharmacy Times
Expert Discusses McKesson's Approach to Supporting Community Pharmacies | McKesson ideaShare - Drug Topics
How McKesson Ruling Will Inform Interpretations Of The TCPA - Law360
McKesson ideaShare 2025: Pharmacy Owner Keri Bates on Career Growth, Technician Pathways, and Building a Sustainable Pharmacy Team - Pharmacy Times
Financial Planning Remains Core Focus to Create Thriving Pharmacy Business | McKesson ideaShare - Drug Topics
Is McKesson Corporation (NYSE:MCK) Trading At A 34% Discount? - Yahoo Finance
Evercore ISI Adjusts Price Target on McKesson to $800 From $760, Maintains Outperform Rating - MarketScreener
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
McKesson stock hits all-time high, reaching $737.0 USD - Investing.com
Why McKesson (MCK) Dipped More Than Broader Market Today - Yahoo Finance
Why Investors Shouldn't Be Surprised By McKesson Corporation's (NYSE:MCK) P/E - simplywall.st
Is It Worth Investing in McKesson (MCK) Based on Wall Street's Bullish Views? - Yahoo Finance
Here's Why McKesson (MCK) is a Strong Growth Stock - Yahoo Finance
McKesson (MCK) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Is McKesson (MCK) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Giving Is in My Blood - McKesson
Nimesh Jhaveri - McKesson
McKesson Corporation Announces First Quarter Fiscal 2026 Earnings Release Date | MCK Stock News - GuruFocus
Biologics by McKesson: Personalized Patient Care - McKesson
McKesson Newsroom: Latest Updates & Announcements - McKesson
Pharmaceutical Distribution & Solutions - McKesson
맥케슨 (MCK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.07%
8.29%
자본화:
|
볼륨(24시간):